KMT2C Polyklonaler Antikörper

KMT2C Polyklonal Antikörper für WB, IHC, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IHC, IF, CoIP, ChIP, ELISA

Konjugation

Unkonjugiert

Publikationen(5)

Kat-Nr. : 28437-1-AP

Synonyme

MLL3, Lysine N methyltransferase 2C, KIAA1506, Homologous to ALR protein, HALR



Geprüfte Anwendungen

Erfolgreiche Detektion in WBK-562-Zellen
Erfolgreiche Detektion in IHChuman ovary cancer tissue
Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

AnwendungVerdünnung
Western Blot (WB)WB : 1:500-1:1000
Immunhistochemie (IHC)IHC : 1:200-1:800
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Produktinformation

28437-1-AP bindet in WB, IHC, IF, CoIP, ChIP, ELISA KMT2C und zeigt Reaktivität mit human

Getestete Reaktivität human
In Publikationen genannte Reaktivitäthuman
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen KMT2C fusion protein Ag28875
Vollständiger Name myeloid/lymphoid or mixed-lineage leukemia 3
Berechnetes Molekulargewicht 541 kDa
Beobachtetes Molekulargewicht541kDa, 269 kDa
GenBank-ZugangsnummerNM_170606
Gene symbol KMT2C
Gene ID (NCBI) 58508
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS with 0.02% sodium azide and 50% glycerol
LagerungsbedingungenBei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Lysine (K)-specific methyltransferase 2C (KMT2C, also known as MLL3) belongs to the mixed-lineage leukemia (MLL) family of histone methyltransferases which methylate the histone 3 tail at lysine 4 (H3K4) as part of the complex proteins associated with Set 1 (COMPASS) complex. Although originally identified as oncogenic fusions in leukemia, genome-wide mutation studies have revealed frequent, presumably loss-of-function, mutations in various members of the MLL family, including MLL2/KMT2B, MLL3/KMT2C, and MLL4/KMT2D in a variety of malignancies, particularly solid tumors. Mechanistic studies of KMT2C in normal cells have focused primarily on its role in enhancer regulation by deposition of H3K4me1 marks.

Protokolle

PRODUKTSPEZIFISCHE PROTOKOLLE
WB protocol for KMT2C antibody 28437-1-APProtokoll herunterladen
IHC protocol for KMT2C antibody 28437-1-APProtokoll herunterladenl
STANDARD-PROTOKOLLE
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen

Publikationen

SpeciesApplicationTitle
humanWB

Int Immunopharmacol

Polysaccharides from Platycodonis Radix ameliorated respiratory syncytial virus-induced epithelial cell apoptosis and inflammation through activation of miR-181a-mediated Hippo and SIRT1 pathways.

Authors - Juan-Juan Li
humanChIP

J Biol Chem

TRIM28 represses renal cell carcinoma cell proliferation by inhibiting TFE3/KDM6A-regulated autophagy

Authors - Tanjing Song
humanWB,IF,CoIP

Adv Sci (Weinh)

TAOK3 Facilitates Esophageal Squamous Cell Carcinoma Progression and Cisplatin Resistance Through Augmenting Autophagy Mediated by IRGM

Authors - Mingchuang Sun
humanWB

Nat Chem Biol

UFL1 triggers replication fork degradation by MRE11 in BRCA1/2-deficient cells

Authors - Tian Tian
Human

BMC Med Genomics

Clinical characteristics and genetic analysis of four pediatric patients with Kleefstra syndrome

Authors - Rong Ren